Category Archives: Business of the drug industry

Pharma: Tax dodgers and price gougers?

KEY POINTS:

Continue reading

Pharma finally admits “digital is important”

KEY TAKEAWAY: GSK and Novartis have gone to the outside to hire senior digital marketing people with CPG experience.  While these moves are long overdue is it enough or is pharma waiting at the airport for their ship to come in? Continue reading

Amgen fights for its new cholesterol drug

KEY TAKEAWAY: A study in JAMA found  “a Markov cohort state-transition model determined that adding evolocumab at current list price to patients receiving standard background therapy was estimated to cost $268 637 per quality-adjusted life-year gained. Sensitivity and scenario analyses demonstrated incremental cost-effectiveness ratios ranging from $100 193 to $488 642 per quality-adjusted life-year.” Will this be enough to sway insurers to say “ok”? Continue reading

Senate Republicans stick it to Medicaid patients while pharma remains silent

It would be a big mistake to call the legislation Senate Republicans released on Thursday a health care bill. It is, plain and simple, a plan to cut taxes for the wealthy by destroying critical federal programs that help provide health care to tens of millions of people. Even with this charade pharma seems happy because “they got what they want” from this President. Continue reading